Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.
Shanghai Fosun Pharmaceutical has announced the composition of its board of directors, which includes 12 members with various roles such as executive, non-executive, and independent non-executive directors. This announcement highlights the company’s governance structure and the roles of each director in different board committees, which could impact the strategic direction and operational oversight of the company.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company based in China, primarily engaged in the pharmaceutical industry. The company focuses on the development, manufacture, and distribution of pharmaceutical products, with a significant market presence in China.
Average Trading Volume: 7,025,116
Technical Sentiment Signal: Buy
Current Market Cap: HK$65.06B
See more insights into 2196 stock on TipRanks’ Stock Analysis page.